EUCTR2007-005392-34-PL进行中（未招募）不适用
A phase III long-term follow-up study to assess antibody persistence and immunological memory in children previously vaccinated with four doses of pneumococcal conjugate vaccine in primary vaccination study 10PN-PD-DIT-001 and booster vaccination study 10PN-PD-DIT-007 and assessment of immune responses following a 2-dose catch-up immunization with GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal vaccine in the 6th year of life. - 10PN-PD-DIT-041 EXT:007 Y1, Y2, Y4
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All subjects must satisfy the following criteria at Visit 1 for the study on long-term follow-up of antibody persistence:
- •Male or female between, and including, 28-32 months of age at the time of first blood sampling.
- •Subjects who previously participated in the 10PN-PD-DIT-001 and the 10PN-PD-DIT-007 studies and who received a full four dose regimen of pneumococcal conjugate vaccine during the primary and booster studies.
- •Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
- •Written informed consent, covering Visits 1, 2 and 3, obtained from the parent or guardian of the subject.
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study
- •All subjects must satisfy the following criteria at Visits 2 and 3:
- •Subject must have participated in Visit 1.
- •All subjects must satisfy the following criteria at Visit 3 for primed subjects or at study entry for unprimed subjects for the study on assessment of immunological memory
- •Written informed consent obtained from the parent or guardian of the subject.
- •Male or female between, and including, 64-68 months of age at the time of vaccination or dose 1, as applicable.
- •Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- •For primed subjects: Having completed the long-term follow-up for antibody persistence in studies 10PN-PD-DIT-041 BST:007 Y1, Y2 and Y4.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The following criteria should be checked at Visit 1 of the long-term follow study for antibody persistence. If any apply, the subject must not be included in the study:
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the blood sampling. (For corticosteroids, this will mean prednisone, or equivalent, higher or equal to 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- •Administration of any additional pneumococcal vaccine since end of 10PN-PD-DIT-007 study.
- •Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the blood sampling.
- •Administration of immunoglobulins and/or any blood products less than 6 months prior to blood sampling.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition since the end of the 10Pn-PD-DIT-007 study, based on medical history and physical examination (no laboratory testing required).
- •The following criteria should be checked at Visit 3 for primed subjects or at study entry for unprimed subjects. If any apply, unprimed subjects must not be included in the study and primed subjects must not participate in study procedures for assessment of immunological memory:
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the vaccination or first dose of study vaccine, as applicable, or planned use during the study period.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination or first dose of study vaccine, as applicable. (For corticosteroids, this will mean prednisone, or equivalent, higher or equal to 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
- •Administration of immunoglobulins and/or any blood products within three months preceding the vaccination or first dose of study vaccine, as applicable, or planned administration during the study period.
- •Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting 30 days before and ending 30 days after vaccination or each dose of study vaccine, as applicable, with the exception of locally recommended vaccines (recommended through national immunization campaigns) such as influenza vaccines.
- •Administration of any pneumococcal vaccine outside studies 10PN-PD-DIT-001 (105553) and 10PN-PD-DIT-007 (107046).
- •For unprimed subjects: previous vaccination with any pneumococcal vaccine.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •History of reactions or allergic disease likely to be exacerbated by any component of the study vaccine.
- •Major congenital defects or serious chronic illness.
- •History of any neurologic disorders or seizures. (Subjects who have had a single uncomplicated febrile convulsion in the past can be included).
- •Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper re
研究者
相似试验
进行中（未招募）
不适用
A phase III long-term follow-up study to assess the immune responses following vaccination at 36-46 months of age with a booster dose of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT) and to evaluate the immunogenicity and safety of a 2-dose catch-up immunization course with the 10Pn-PD-DiT vaccine in the fourth year of life. - 10PN-PD-DIT-046 EXT:002 Y2A booster vaccination study against Streptococcus pneumoniae in subjects aged 36-46 months and a two-dose vaccination against Streptococcus pneumoniae of age-matched unprimed children.EUCTR2008-003950-14-SEGlaxoSmithKline Biologicals210
进行中（未招募）
1 期
A phase III long-term follow-up study to assess the immune responses following vaccination at 36-46 months of age with a booster dose of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT) and to evaluate the immunogenicity and safety of a 2-dose catch-up immunization course with the 10Pn-PD-DiT vaccine in the fourth year of life. - 10PN-PD-DIT-046 EXT:002 Y2A booster vaccination study against Streptococcus pneumoniae in subjects aged 36-46 months and a two-dose vaccination against Streptococcus pneumoniae of age-matched unprimed children.EUCTR2008-003950-14-SKGlaxoSmithKline Biologicals210
进行中（未招募）
不适用
A phase III long-term follow-up study to assess immunological memory induced following primary and booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT), through evaluation of early antibody responses after an additional dose of 10Pn-PD-DiT at 40-48 months of age, to evaluate in the fourth year of life, the immunogenicity and safety of a 2-dose catch-up immunization course with the 10Pn-PD-DiT vaccine and the impact of pneumococcal vaccination on nasopharyngeal carriage. - 10PN-PD-DIT-042 EXT 014Subjects aged 31-44 months previously vaccinated with GSK Biologicals’ 10Pn-PD-DiT vaccine and age-matched unprimed children who participated in study 10PN-PD-DIT-014 (107137).EUCTR2008-008104-41-CZGlaxoSmithKline Biologicals690
进行中（未招募）
1 期
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisSubjects with generalized pustular psoriasisMedDRA version: 20.0Level: PTClassification code 10037575Term: Pustular psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-001448-90-FRAnaptysBio Inc.45
进行中（未招募）
1 期
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisSubjects with generalized pustular psoriasisMedDRA version: 20.0Level: PTClassification code 10037575Term: Pustular psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-001448-90-DEAnaptysBio Inc.45